Andrew Green Acquires AORT Shares in Recent Transaction
SVP Andrew Green purchased 44,001 shares of AORT on June 11, 2026, for $589,076.59.
Key Points
- Andrew Green, SVP of Regulatory and Quality at AORT, bought 44,001 shares on June 11, 2026, for $589,076.59.
- AORT shares were trading at $20.35, with a recent insider purchase reflecting potential confidence.
- Analysts from Citizens and Needham maintain a 'buy' rating, with price targets up to $58.
Andrew Green, the Senior Vice President of Regulatory and Quality at AORT, made a significant purchase of the company's stock on June 11, 2026. He bought 44,001 shares at an average price of $13.39 per share, totaling approximately $589,076.59. This transaction was not part of a pre-planned trading program.
Insider Buying and Selling at Artivion, Inc.
On June 11, 2026, Andrew Green acquired 44,001 shares of AORT, valued at $589,076.59. The purchase was made at an average price of $13.39 per share. Anthony Semedo also made several transactions, buying and selling shares in early June and May.
Other Institutional Activity in AORT
Institutional investors have been active in AORT as well. BlackRock, Inc. grew its holdings by 106,735 shares, reaching a total of 6,474,854 shares valued at about $237.1 million. FMR LLC added 41,560 shares for a total of 2,583,427 shares worth roughly $94.6 million. Meanwhile, Nomura Asset Management International Inc. reduced its position by 157,325 shares, leaving it with 2,456,146 shares valued at $89.9 million. Morgan Stanley and State Street Corp also increased their holdings.
AORT Stock Snapshot
Shares of AORT were trading around $20.35. The stock has seen a range in price over the past year, with institutional investors adjusting their positions recently. AORT's market activity reflects a broader interest in its performance and potential growth.
Analysts Set New Price Targets
On May 8, 2026, Citizens and Needham both maintained their 'buy' ratings on AORT, with price targets of $48 and $44, respectively. Earlier in April, Ladenburg Thalmann upgraded the stock to a 'buy' with a target of $42. Analysts overall seem optimistic, with a consensus leaning towards a 'buy' recommendation.
Bottom Line
Andrew Green's purchase of AORT shares highlights insider confidence in the company's prospects. Institutional investors are also actively adjusting their positions, reflecting ongoing interest in AORT's potential. Analysts maintain a positive outlook, with several firms reiterating 'buy' ratings and setting ambitious price targets. As always, insider transactions and analyst ratings are key metrics investors watch, though they reflect past decisions and projections.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.